Abstract:Objective To detect the platelet inhibition of aspirin and clopidogrel in patients after percutaneous transluminal angioplasty and stenting(PTAS) using a thromboelastograph(TEG) instrument in order to guide the individualized adjustment of anti-platelet aggregation drugs after PTAS.Methods The clinical data of 65 patients with ischemic stroke or transient ischemic attack included from Nanjing Stroke Registry Program were analyzed retrospectively.Venous blood samples were collected at day 3 after PTAS.A TEG instrument was used to detect arachidonic acid(AA)-induced inhibition rate of platelet aggregation and adenosine diphosphate(ADP) receptor-induced inhibition rate of platelet aggregation.The AA pathway and ADP receptor-induced inhibition rate of platelet aggregation,as well as the response differences of the patients between aspirin and clopidogrel therapy were compared.Results ①The inhibition rate(80±28%) of aspirin for the AA pathway was significantly higher than that(53±31%) of clopidogrel for the ADP receptor pathway(P<0.01).②Of the 65 patients,the therapeutic effects in 45(69.2%),8(12.3%),7(10.8%) and 5(7.7%) patients were good,effective,low response,and ineffective in the aspirin group,and those in 19(29.2%),14(21.5%),23(35.4%) and 9(13.8%) were good,effective,low response,and ineffective in the clopidogrel group.Of those who had a good response to aspirin,3 had no response to clopidogrel and 14 had low response to clopidogrel;of those who had a good response to clopidogrel,all responded well or effective to aspirin.Of those who had low response to clopidogrel,4 had low response to aspirin,5 had a good response to aspirin,and 14 had good results.The two efficacies had some relevance(χ2=33.311,P<0.01).③A total of 53 patients had a good+effective response to aspirin,and 12 had low response+ineffective to aspirin,while 33 and 32 patients had good+effective and low response+ineffective to clopidogrel.There was significant difference in efficacy between the two drugs(χ2m=15.042,P<0.01).Conclusion Using TEG instrument to detect the inhibition rate of platelet aggregation in patients after PTAS is beneficial to guide the development of therapeutic scheme for individualized anti-platelet aggregation in clinical practice.The inhibitory effect of platelet aggregation of aspirin after PTAS is stronger than that of clopidogrel.The patients show differential responses to aspirin and clopidogrel therapy.Some patients who have low response to clopidogrel may respond well or may be effective to aspirin.

Analysis of Platelet Inhibition Rate in Patients With Stable Angina Pectoris Combining Diabetes Mellitus

Impact of Diabetes on Platelet Function in Acute Ischemic Stroke Patients Taking Dual Antiplatelet Therapy

Clinical analysis of clopidogrel resistance in patients with coronary heart disease after percutaneous coronary intervention

Evaluation of the efficacy of anti-platelet aggregation drugs in patients using thromboelastograph after percutaneous transluminal angioplasty and stenting

Risk of Bleeding and Ischemia in Elderly East Asian Patients with Diabetes Mellitus Treated with either Clopidogrel or Ticagrelor: From the Korean Acute Myocardial Infarction Registry-V

Clinical usefulness of thrombelastograph in patients with acute coronary syndrome

Platelet-fibrin Clot Strength Measured by Thromboelastography Could Predict Hypercoagulability and Antiplatelet Effects in Patients after Percutaneous Coronary Intervention.

Platelet reactivity by thromboelastography in patients undergoing percutaneous coronary intervention

Effect of Tirofiban Combined with Enoxaparin in Patients with Diabetes Mellitus Complicated Non - ST Segment Elevation Acute Coronary Syndrome

Long-term Effect of Clopidogrel in Patients with and Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Antiplatelet Drugs Resistance after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome and Chronic Kidney Disease

Implication of diabetic status on platelet reactivity and clinical outcomes after drug-eluting stent implantation: results from the PTRG-DES consortium

Diabetes and Outcomes Following Personalized Antiplatelet Therapy in Coronary Artery Disease Patients Who Have Undergone PCI

Association Between Insulin Receptor Substrate-1 Polymorphisms and High Platelet Reactivity with Clopidogrel Therapy in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus.

Impact of Diabetes Mellitus on Antithrombotic Management Patterns and Long-Term Clinical Outcomes in Patients with Acute Coronary Syndrome: Insight from the Epicor Asia Study

Residual Platelet Reactivity is Preferred over Platelet Inhibition Rate in Monitoring Antiplatelet Efficacy: Insights Using Thrombelastography

The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy

Optimal Strategy for Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation in High-Risk “TWILIGHT-like” Patients With Diabetes Mellitus

Platelet Inhibition with Ticagrelor Versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes

Primary Percutaneous Coronary Intervention in Patients With Type 2 Diabetes With Late/Very Late Stent Thrombosis and de novo Lesions: A Single-Center Observational Cohort Study of Clinical Outcomes and Influencing Factors

Long-term effect of triple antiplatelet therapy for diabetic patients after percutaneous coronary intervention